Tech Company Financing Transactions
Receptor BioLogix Funding Round
On 4/28/2005, Receptor BioLogix raised $33.6 million in Series A funding from Skyline Ventures, Domain Associates and EW Healthcare Partners.
Transaction Overview
Company Name
Announced On
4/28/2005
Transaction Type
Venture Equity
Amount
$33,600,000
Round
Series A
Investors
Skyline Ventures (Lead Investor)
EW Healthcare Partners (Jeffrey Himawan)
Proceeds Purpose
Receptor BioLogix plans to use the financial proceeds to advance its lead therapeutic candidate, Dimercept", a broad-spectrum anticancer agent representing a new class of biothera?peutics called Intron Fusion Proteins (IFP") that are capable of modulating disease pathways involved in cancer, inflammatory and autoimmune diseases.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
PO Box 1210
Mountain View, CA 94042
USA
Mountain View, CA 94042
USA
Phone
Website
Email Address
Overview
Receptor BioLogix Inc., a biopharmaceutical company focused on developing newly discovered protein therapeutics to treat cancer, autoimmune, metabolic and other diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Financial Officer
Janet Swearson
Browse more venture capital transactions:
Prev: 4/28/2005: Channel M venture capital transaction
Next: 5/2/2005: Traffic.com venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs